Our results showed similar risks of COVID-19 infection, hospitalization and mortality in psoriasis patients under IL-17 inhibitors compared with those under methotrexate, which indirectly demonstrated the potential protective effect of IL-17 inhibitors on COVID-19 infection and progression in patients with psoriasis. The gene discussed is IL17A; the disease is psoriasis.